The use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in patients with metabolic dysfunction–associated steatotic liver disease (MASLD) was associated with a reduced risk for new ...

Liver failure, which can start suddenly or develop slowly, has a high mortality risk because of the swift onset of hepatocellular dysfunction. At least 30,000 patients in the USA and in Europe are ...